Image de couverture de livre

Editorial: Obesity and Outcomes on Advanced Therapy in Ulcerative Colitis—The Fat of the Matter: Authors' Reply

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Aakash Desai, Priya Sehgal
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	Alimentary Pharmacology & Therapeutics
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Editorial: Obesity and Outcomes on Advanced Therapy in Ulcerative Colitis—The Fat of the Matter
par: Anish J. Kuriakose Kuzhiyanjal, et autres
Publié: (2025)

Obesity Is Associated With Worsened Outcomes in Patients With Ulcerative Colitis on Advanced Therapies: A Propensity Matched Cohort Study From the U.S.
par: Aakash Desai, et autres
Publié: (2025)

Editorial: Real‐World Effectiveness of Mirikizumab in Ulcerative Colitis—A Valuable but Preliminary Glimpse. Authors' Reply
par: Shinichiro Shinzaki, et autres
Publié: (2025)

Editorial: Ulcerative Colitis Management in the Biologic Era–Data From the English Healthcare Databases. Authors' Reply
par: J. Couch, et autres
Publié: (2025)

Editorial: Effectiveness and Safety of Ustekinumab in Ulcerative Colitis—Where We Are Now in Real Life. Authors' Reply
par: María Chaparro, et autres
Publié: (2024)

Editorial: Dual Advanced Therapy in Refractory Ulcerative Colitis—Hope Beyond Monotherapy
par: Ahmed B. Bayoumy, et autres
Publié: (2025)

Letter: Thiopurines the Silent Workhorse for Many Patients After a Flare of Ulcerative Colitis. Authors' Reply
par: Ankit Kumar, et autres
Publié: (2026)

Letter: Enhancing Predictive Models for Paediatric Ulcerative Colitis—Addressing Socioeconomic, Environmental and Clinical Factors. Authors' Reply
par: Merle Claßen, et autres
Publié: (2024)

Editorial: Association of Antibiotic Exposure With Microscopic Colitis—Authors' Reply
par: Máté Szilcz, et autres
Publié: (2025)

Letter: A Patient Centric Approach to Tapering Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis. Authors' Reply
par: Amol N. Patil, et autres
Publié: (2026)

Editorial: Striving for Equitable Care in Ulcerative Colitis
par: Edward L. Barnes
Publié: (2025)

Editorial: Getting to the Heart of the Matter in IBD—Authors' Reply
par: Ramin Ebrahimi, et autres
Publié: (2025)

Azathioprine or Tofacitinib as Maintenance Therapy in Corticosteroid‐Responsive Acute Severe Ulcerative Colitis
par: Arshdeep Singh, et autres
Publié: (2025)

Letter: Steroid Tapering in Ulcerative Colitis: The Importance of Disease Severity and Maintenance Therapy
par: Rónán O'Connor, et autres
Publié: (2026)

Editorial: Assessing the Prognosis of Patients With HBV and ACLF—Comorbidities Matter. Authors' Reply
par: Jiong Yu, et autres
Publié: (2024)

Editorial: Evolving Trends in Ulcerative Colitis Management—Insights From the Lothian Cohort
par: Shintaro Akiyama
Publié: (2025)

Editorial: The Appendix—A Dead End for Treating Ulcerative Colitis, After All?
par: Johan D. Söderholm
Publié: (2025)

Letter: Temporal Trends in the Rate of Colectomy in Ulcerative Colitis
par: Richard Pollok
Publié: (2025)

Editorial: Combination Therapies for MASH : A Step Forward or More Complexity? Authors' Reply
par: Eric Lawitz, et autres
Publié: (2025)

Editorial: Real‐World Effectiveness of Mirikizumab in Ulcerative Colitis—A Valuable but Preliminary Glimpse
par: Mark A. Ainsworth, et autres
Publié: (2025)

Editorial: Advancing HCC Surveillance in Hepatitis B With Biomarker‐Based Strategy—Authors' Reply
par: Tanat Saeoui, et autres
Publié: (2025)

Editorial: Real‐World Evidence of Upadacitinib—An Effective Induction Therapy for Crohn's Disease? Authors' Reply
par: Nicolas Richard, et autres
Publié: (2025)

Editorial: Spontaneous Bacterial Peritonitis—Redrawing Empiric Therapy in the Era of Multidrug Resistance. Authors' Reply
par: Rohit Mehtani, et autres
Publié: (2026)

Meta‐Analysis: Exclusive Enteral Nutrition in Adults With Ulcerative Colitis
par: Matthew K. W. Chu, et autres
Publié: (2025)

Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
par: Antoine Meyer, et autres
Publié: (2025)

Long‐Term Outcomes of an Infliximab‐First Versus Vedolizumab‐First Treatment Strategy in Biologic‐Naïve Patients With Ulcerative Colitis
par: Austin Haynesworth, et autres
Publié: (2024)

Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
par: Zhidong Zhou, et autres
Publié: (2025)

Editorial: Understanding Factors Associated With Abdominal Pain in Ulcerative Colitis—No Surprises But the Usual Suspects Need Greater Attention
par: Weilun Gao, et autres
Publié: (2024)

Efficacy and Safety of Vedolizumab and Tofacitinib ( VETO ) Combination Therapy in Refractory Ulcerative Colitis Unresponsive to Anti‐ TNF and a Second‐Line Advanced Therapy: A Prospective Cohort Nested Within a Randomised Trial
par: Pardhu Bharath Neelam, et autres
Publié: (2025)

Temporal Trends in Medical and Surgical Management of Ulcerative Colitis in England: 2003–2020
par: J. Couch, et autres
Publié: (2025)

Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply
par: Jianhui Zhao, et autres
Publié: (2024)

Editorial: To Stop or Not to Stop, Is It Still a Question? Authors' Reply
par: Jeongkuk Seo, et autres
Publié: (2024)

Editorial: Predicting Hepatocellular Cancer in Clinical Practice. Authors' Reply
par: Shuaibing Ying, et autres
Publié: (2026)

Editorial: Navigating the Beta‐Blocker Dilemma in Advanced Liver Cirrhosis—When Is the Right Time to Discontinue? Authors' Reply
par: Ting Wang, et autres
Publié: (2024)

Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease—Authors' Reply
par: Jessica D. Lee, et autres
Publié: (2025)

Editorial: Beyond Viral Eradication—Cardiometabolic Risk and Cardiovascular Outcomes After SVR in Chronic Hepatitis C. Authors' Reply
par: Pei‐Chien Tsai, et autres
Publié: (2026)

Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT‐UC Consortium
par: Parambir S. Dulai, et autres
Publié: (2024)

Letter: Exclusive Enteral Nutrition in Ulcerative Colitis—The Path Ahead Needs Careful Consideration
par: Sarah Melton, et autres
Publié: (2025)

Letter: Increased Prevalence of Visceral Obesity in Nonresponder Patients With Primary Biliary Cholangitis Based on Computed Tomography—Authors' Reply
par: Conrado Fernandez‐Rodriguez, et autres
Publié: (2024)

Editorial: Efficacy of Pharmacological Compared With Dietary Therapy for Patients With Irritable Bowel Syndrome—It Is Nice to Have a Choice. Authors' Reply
par: Kee Huat Chuah, et autres
Publié: (2025)